{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:17:53Z","timestamp":1795043873797,"version":"4.10.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alcohol use disorder (AUD) affects nearly half a billion people globally and is associated with significant physical and psychiatric comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and obesity, have shown promise in modulating reward-related brain pathways, suggesting potential benefits in the management of AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis, registered in PROSPERO and conducted per PRISMA guidelines, assessed the effects of GLP-1RA use on AUD and alcohol-related outcomes in adults with obesity or type 2 diabetes mellitus. Five databases (PubMed, Embase, Web of Science, Scopus, and Cochrane Library) were searched up to September 30, 2025. Random-effects models were applied, and sensitivity analyses examined result stability. No subgroup or meta-regression analyses were performed owing to the small number of eligible studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five observational cohort studies (three on AUD diagnosis, two on alcohol-related hospitalization) were included, with sample sizes ranging from 4,321 to &gt;\u200953,000 participants. GLP-1RA use was associated with a 28% lower risk of AUD diagnosis (HR\u2009=\u20090.72, 95% CI 0.59\u20130.89; I\u00b2 = 65%). For alcohol-related hospitalization, a non-significant reduction was observed (HR\u2009=\u20090.76, 95% CI 0.57\u20131.01; I\u00b2 = 77%). Leave-one-out sensitivity analyses confirmed the direction and magnitude of the AUD finding but highlighted the limited evidence base for hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1RA use was associated with a reduced risk of AUD diagnosis, with a possible but non-significant reduction in alcohol-related hospitalization. Effects may be mediated through modulation of mesolimbic reward pathways and the gut\u2013brain axis. Further large-scale trials are warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-02006-x","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:34:04Z","timestamp":1767875644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Amir","family":"Nasrollahizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Kheiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepide","family":"Javankiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadra","family":"Kheiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Fatemeh","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Amini-Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"10200","key":"2006_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(19)31775-1","volume":"394","author":"AF Carvalho","year":"2019","unstructured":"Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394(10200):781\u201392.","journal-title":"Lancet"},{"issue":"9662","key":"2006_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","volume":"373","author":"MA Schuckit","year":"2009","unstructured":"Schuckit MA. Alcohol-use disorders. Lancet. 2009;373(9662):492\u2013501.","journal-title":"Lancet"},{"issue":"9","key":"2006_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S2468-1253(24)00239-5","volume":"9","author":"G The Lancet","year":"2024","unstructured":"The Lancet G, amp. Hepatology. Global progress towards alcohol harm reduction insufficient. Lancet Gastroenterol Hepatol. 2024;9(9):773.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10007","key":"2006_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(15)00235-4","volume":"386","author":"A Smyth","year":"2015","unstructured":"Smyth A, Teo KK, Rangarajan S, O\u2019Donnell M, Zhang X, Rana P, et al. Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. Lancet. 2015;386(10007):1945\u201354.","journal-title":"Lancet"},{"key":"2006_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.drugalcdep.2018.01.019","volume":"186","author":"A Peacock","year":"2018","unstructured":"Peacock A, Eastwood B, Jones A, Millar T, Horgan P, Knight J, et al. Effectiveness of community psychosocial and pharmacological treatments for alcohol use disorder: a national observational cohort study in England. Drug Alcohol Depend. 2018;186:60\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2006_CR6","first-page":"141","volume":"53","author":"G Coriale","year":"2018","unstructured":"Coriale G, Fiorentino D, De Rosa F, Solombrino S, Scalese B, Ciccarelli R, et al. Treatment of alcohol use disorder from a psychological point of view. Rivista Di Psichiatria. 2018;53(3):141\u20138.","journal-title":"Rivista Di Psichiatria"},{"issue":"17","key":"2006_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.2023.19761","volume":"330","author":"M McPheeters","year":"2023","unstructured":"McPheeters M, O\u2019Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA. 2023;330(17):1653\u201365.","journal-title":"JAMA"},{"issue":"12","key":"2006_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","volume":"26","author":"K Mann","year":"2016","unstructured":"Mann K, Torup L, S\u00f8rensen P, Gual A, Swift R, Walker B, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016;26(12):1941\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"2006_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jama.2018.11406","volume":"320","author":"HR Kranzler","year":"2018","unstructured":"Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815\u201324.","journal-title":"JAMA"},{"issue":"3","key":"2006_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.pharmthera.2006.02.001","volume":"111","author":"M Heilig","year":"2006","unstructured":"Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006;111(3):855\u201376.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"2006_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","volume":"45","author":"LA Ray","year":"2019","unstructured":"Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124\u201340.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"8","key":"2006_CR12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K","volume":"20","author":"B Ahr\u00e9n","year":"1998","unstructured":"Ahr\u00e9n B. Glucagon-like peptide\u20101 (GLP\u20101): A gut hormone of potential interest in the treatment of diabetes. BioEssays. 1998;20(8):642\u201351.","journal-title":"BioEssays"},{"issue":"1","key":"2006_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2337\/db18-0729","volume":"68","author":"MK Holt","year":"2019","unstructured":"Holt MK, Richards JE, Cook DR, Brierley DI, Williams DL, Reimann F, et al. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes. 2019;68(1):21\u201333.","journal-title":"Diabetes"},{"key":"2006_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","volume":"15","author":"M Shah","year":"2014","unstructured":"Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15:181\u20137.","journal-title":"Rev Endocr Metab Disord"},{"key":"2006_CR15","doi-asserted-by":"crossref","unstructured":"Karimi MA, Gholami Chahkand MS, Dadkhah PA, Sheikhzadeh F, Yaghoubi S, Esmaeilpour Moallem F et al. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Front Pharmacol. 2025;Volume 16\u20132025.","DOI":"10.3389\/fphar.2025.1438318"},{"issue":"20","key":"2006_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"issue":"1","key":"2006_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010135","volume":"13","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Nikolaou M. Integrated management of Cardiovascular\u2013Renal\u2013Hepatic\u2013Metabolic syndrome: expanding roles of SGLT2is, GLP-1 RAs, and GIP\/GLP-1 RAs. Biomedicines. 2025;13(1):135.","journal-title":"Biomedicines"},{"issue":"2","key":"2006_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","volume":"37","author":"RZ Litten","year":"2016","unstructured":"Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subst Abuse. 2016;37(2):286\u201398.","journal-title":"Subst Abuse"},{"key":"2006_CR19","unstructured":"Alessi JP. Brain responses to sugar: implications for alcohol use disorder and obesity. Indiana University-Purdue University Indianapolis. 2024."},{"key":"2006_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.11.005","volume":"196","author":"E Jerlhag","year":"2019","unstructured":"Jerlhag E. Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse. Pharmacol Ther. 2019;196:1\u201314.","journal-title":"Pharmacol Ther"},{"key":"2006_CR21","doi-asserted-by":"crossref","unstructured":"Dalton M, Buckland N, Blundell J. Psychobiology of obesity: eating behavior and appetite control. Clin Obes Adults Child. 2022;99\u2013112.","DOI":"10.1002\/9781119695257.ch8"},{"key":"2006_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.psychres.2016.10.010","volume":"246","author":"D Vancampfort","year":"2016","unstructured":"Vancampfort D, Mugisha J, Hallgren M, De Hert M, Probst M, Monsieur D, et al. The prevalence of diabetes mellitus type 2 in people with alcohol use disorders: a systematic review and large scale meta-analysis. Psychiatry Res. 2016;246:394\u2013400.","journal-title":"Psychiatry Res"},{"issue":"19","key":"2006_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863","volume":"7","author":"MK Klausen","year":"2022","unstructured":"Klausen MK, Jensen ME, M\u00f8ller M, Le Dous N, Jensen A-M, Zeeman VA, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863.","journal-title":"JCI Insight"},{"key":"2006_CR24","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"2006_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102726","author":"R De Giorgi","year":"2024","unstructured":"De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClin Med. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102726.","journal-title":"eClin Med"},{"key":"2006_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-48780-6.","journal-title":"Nat Commun"},{"issue":"10","key":"2006_CR27","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/oby.70001","volume":"33","author":"O Adeniran","year":"2025","unstructured":"Adeniran O, Nieto LM, Amadi C, Shepherd K, Kirkpatrick J, Farah K, et al. Alcoholic use disorder outcomes after Roux-en-Y gastric bypass in patients taking GLP-1 ras: a multicenter analysis. Obesity. 2025;33(10):1886\u201394.","journal-title":"Obesity"},{"issue":"1","key":"2006_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","volume":"82","author":"M L\u00e4hteenvuo","year":"2025","unstructured":"L\u00e4hteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatr. 2025;82(1):94\u20138.","journal-title":"JAMA Psychiatr"},{"issue":"6","key":"2006_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40265-025-02177-x","volume":"85","author":"F Al-Moussally","year":"2025","unstructured":"Al-Moussally F, Khan S, Katukuri V, Kinaan M, Mansi IA. Association of glucagon-like peptide-1 receptor agonist with progression to liver cirrhosis and alcohol-related admissions in patients with alcohol use disorder and diabetes: a retrospective cohort study. Drugs. 2025;85(6):813\u201325.","journal-title":"Drugs"},{"issue":"2","key":"2006_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/add.16679","volume":"120","author":"F Qeadan","year":"2025","unstructured":"Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis. Addiction. 2025;120(2):236\u201350.","journal-title":"Addiction"},{"issue":"8","key":"2006_CR31","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.03.16","volume":"6","author":"H Azam","year":"2018","unstructured":"Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018;6(8):148.","journal-title":"Ann Transl Med"},{"issue":"2","key":"2006_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/jamasurg.2022.6410","volume":"158","author":"N Mahmud","year":"2023","unstructured":"Mahmud N, Panchal S, Abu-Gazala S, Serper M, Lewis JD, Kaplan DE. Association between bariatric surgery and alcohol use\u2013related hospitalization and all-cause mortality in a veterans affairs cohort. JAMA Surg. 2023;158(2):162\u201371.","journal-title":"JAMA Surg"},{"issue":"7","key":"2006_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15070702","volume":"15","author":"TS Oesterle","year":"2025","unstructured":"Oesterle TS, Ho M-F. Glucagon-like peptide-1 receptor agonists: a new frontier in treating alcohol use disorder. Brain Sci. 2025;15(7):702.","journal-title":"Brain Sci"},{"issue":"10152","key":"2006_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","volume":"392","author":"MG Griswold","year":"2018","unstructured":"Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet. 2018;392(10152):1015\u201335.","journal-title":"Lancet"},{"issue":"22","key":"2006_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419","volume":"8","author":"L Probst","year":"2023","unstructured":"Probst L, Monnerat S, Vogt D R, Lengsfeld S, Burkard T, Meienberg A, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023;8(22):e170419.","journal-title":"JCI Insight"},{"issue":"1","key":"2006_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11585880-000000000-00000","volume":"50","author":"M Fineman","year":"2011","unstructured":"Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50(1):65\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"2006_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/acer.70041","author":"ME Jensen","year":"2025","unstructured":"Jensen ME, Klausen MK, Bergmann ML, Knudsen GM, Vilsb\u00f8ll T, Stove C, et al. Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption. Alcohol Clin Exp Res. 2025. https:\/\/doi.org\/10.1111\/acer.70041.","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"2006_CR38","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/dom.16152","volume":"27","author":"M O\u2019Farrell","year":"2025","unstructured":"O\u2019Farrell M, Almohaileb FI, le Roux CW. Glucagon-like peptide-1 analogues reduce alcohol intake. Diabetes Obes Metabolism. 2025;27(3):1601\u20134.","journal-title":"Diabetes Obes Metabolism"},{"key":"2006_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102920","author":"M Subhani","year":"2024","unstructured":"Subhani M, Dhanda A, King JA, Warren FC, Creanor S, Davies MJ, et al. Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. eClin Med. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102920.","journal-title":"eClin Med"},{"key":"2006_CR40","doi-asserted-by":"crossref","unstructured":"Richards JR, Dorand MF, Royal K, Mnajjed L, Paszkowiak M, Simmons WK. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: A case series. J Clin Psychiatry. 2023;85(1).","DOI":"10.4088\/JCP.23m15068"},{"key":"2006_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114622","volume":"283","author":"S Badulescu","year":"2024","unstructured":"Badulescu S, Tabassum A, Le GH, Wong S, Phan L, Gill H, et al. Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review. Physiol Behav. 2024;283:114622.","journal-title":"Physiol Behav"},{"key":"2006_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2025.105512","volume":"4","author":"AJ Krupa","year":"2025","unstructured":"Krupa AJ. Curbing the appetites and restoring the capacity for satisfaction: the impact of GLP-1 agonists on the reward circuitry. Neuroscience Applied. 2025;4:105512.","journal-title":"Neuroscience Applied"},{"key":"2006_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312","volume":"207","author":"ViN Bruns","year":"2024","unstructured":"Bruns Vi N, Tressler EH, Vendruscolo LF, Leggio L, Farokhnia M. IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharmacol Res. 2024;207:107312.","journal-title":"Pharmacol Res"},{"key":"2006_CR44","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaf028","author":"E Jerlhag","year":"2025","unstructured":"Jerlhag E. GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder. Endocrinology. 2025. https:\/\/doi.org\/10.1210\/endocr\/bqaf028.","journal-title":"Endocrinology"},{"key":"2006_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170671","author":"V Chuong","year":"2023","unstructured":"Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.170671.","journal-title":"JCI Insight"},{"issue":"2","key":"2006_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","volume":"236","author":"M Thomsen","year":"2019","unstructured":"Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A. Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring Vervet monkeys. Psychopharmacology. 2019;236(2):603\u201311.","journal-title":"Psychopharmacology"},{"issue":"1","key":"2006_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","volume":"242","author":"A Fink-Jensen","year":"2025","unstructured":"Fink-Jensen A, W\u00f6rtwein G, Klausen MK, Holst JJ, Hartmann B, Thomsen M, et al. Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male Vervet monkeys. Psychopharmacology. 2025;242(1):63\u201370.","journal-title":"Psychopharmacology"},{"issue":"4","key":"2006_CR48","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s11064-023-04093-6","volume":"49","author":"W Liu","year":"2024","unstructured":"Liu W, Wang Z, Wang W, Wang Z, Xing Y, H\u00f6lscher C. Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice. Neurochem Res. 2024;49(4):1061\u201375.","journal-title":"Neurochem Res"},{"key":"2006_CR49","doi-asserted-by":"publisher","first-page":"146562","DOI":"10.1016\/j.brainres.2019.146562","volume":"1727","author":"E Jerlhag","year":"2020","unstructured":"Jerlhag E. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Brain Res. 2020;1727:146562.","journal-title":"Brain Res"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02006-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:35:34Z","timestamp":1769067334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2006"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02006-x","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study is a systematic review and meta-analysis of previously published data, ethical approval was not required by the authors\u2019 institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}